ISSUE 94 I MAY 2020

In association with

an (in)active

pill problem

Medications are supposed to make patients feel better, but inactive ingredients are creating unexpected problems

Where are the whistleblowers?

Creating a pharma playbook

2020: The year of the spin out?

Where are the whistleblowers?

Creating a pharma playbook

2020: The year of the spin out?

02/24/2024 12:20:25
  • Home | An (in)active pill problem
  • Editorial
  • SHL Group Company Insight
  • Scandinavian Health
  • Contents
  • NSF
  • News
  • Almac
  • Covid-19 executive briefing by GlobalData
  • Gerteis Company Insight
  • Gerteis
  • Digital biomarkers are emerging as important predictive tools to support the glo
  • Accurate Biometrics Company Insight
  • Accurate Biometrics
  • Almost 70 potential Covid-19 drug and experimental compound candidates identified
  • Datwyler Company Insight
  • Datwyler
  • Risk assessment of Covid-19 on patients suffering from IBD
  • Zenatek
  • The pharma industry briefing
  • Fargo
  • Another bump in the road for mumps treatment
  • Last Technology
  • From Covid-19 to SARS: what becomes of the whistleblowers?
  • Butterworth
  • Peptomyc: the quest for a ‘universal’ cancer treatment
  • Q&A: is pharma ready to address the health effects of climate change?
  • Modality Solutions
  • Not-so-inactive ingredients: a sore spot for patients?
  • Beyond M&As: will 2020 be the year of the spin-off?
  • VEGA Company Insight
  • VEGA Australia
  • Q&A with Genocea: improving cancer treatment with precise, personalised targets
  • Mimotopes
  • Pharma Playbook: an inside look at Signals Analytics vast therapeutic database
  • ILC Dover
  • Deals in brief powered by GlobalData
  • The key list powered by GlobalData
  • Global markets and indices powered by GlobalData
  • Macro-economic indicators (1 of 2) powered by GlobalData
  • Macro-economic indicators (2 of 2) powered by GlobalData
  • Events
  • Next issue
04/23/2020 00:00:00